Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
350
Website
HALO Metrics
BasicAdvanced
$7.4B
15.98
$3.76
1.15
-
Price and volume
Market cap
$7.4B
Beta
1.15
52-week high
$70.51
52-week low
$42.01
Average daily volume
2.3M
Financial strength
Current ratio
8.392
Quick ratio
6.999
Long term debt to equity
318.667
Total debt to equity
318.667
Interest coverage (TTM)
32.99%
Profitability
EBITDA (TTM)
673.223
Gross margin (TTM)
76.17%
Net profit margin (TTM)
44.76%
Operating margin (TTM)
55.10%
Effective tax rate (TTM)
19.77%
Revenue per employee (TTM)
$3,100,000
Management effectiveness
Return on assets (TTM)
18.49%
Return on equity (TTM)
147.06%
Valuation
Price to earnings (TTM)
15.984
Price to revenue (TTM)
6.976
Price to book
15.34
Price to tangible book (TTM)
-23.23
Price to free cash flow (TTM)
15.257
Free cash flow yield (TTM)
6.55%
Free cash flow per share (TTM)
3.938
Growth
Revenue change (TTM)
25.65%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
31.99%
10-year revenue growth (CAGR)
29.45%
3-year earnings per share growth (CAGR)
7.82%
10-year earnings per share growth (CAGR)
23.43%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Bulls say / Bears say
Halozyme Therapeutics reported a 35% increase in revenue and a 54% growth in net income for Q1 2025, leading to an upward revision of its full-year financial guidance. (Seeking Alpha)
The European Commission approved Bristol Myers Squibb's subcutaneous Opdivo® (nivolumab) co-formulated with Halozyme's ENHANZE® technology for multiple solid tumor indications, potentially expanding Halozyme's market reach. (Halozyme News)
Analysts have set an average 12-month price target of $63.56 for HALO stock, indicating a potential upside of approximately 17.7% from the current price. (Stock Analysis)
Halozyme is engaged in a patent dispute with Merck over the subcutaneous formulation of Keytruda, which could lead to costly litigation and potential revenue loss if the outcome is unfavorable. (Reuters)
The company's total debt stands at $1.54 billion, resulting in a high debt-to-equity ratio of 318.67%, which may raise concerns about financial leverage and risk. (Forbes)
Recent analyst downgrades, such as Morgan Stanley's reduction of the price target from $73 to $62, suggest potential concerns about the company's future performance. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $7.4B as of August 01, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 15.98 as of August 01, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.